Zentiva – your partner for 3rd millenium



- Introduction
- Sicomed & Zentiva
- The role of national player in healthcare system
- Drugs cathegorization and reimbursement
- Conclusion



To develop, produce and sell pharmaceutical products to improve quality of human life




We extend and make accessible the high quality and modern treatment




To be and be perceived as the leading pharmaceutical provider in the Central and Eastern Europe



Zentiva managerial structure










- A Leading pharmaceutical company in the region of Central
 - and Eastern Europe
- Market leader in Czech and Slovak Republic
- The fastest growing company in Poland and Estonia
- Significant sales growth in Russia and Lithuania




icomed: A Quality Asset with Strong Top Line Growth

Over the past five years, Sicomed has:

- Rationalised product portfolio from c.240 to c.130 products
- Modernised the portfolio, primarily through inlicensing
- Built strong OTC portfolio
- Decreased hospital sales from c.50% to c.15% of total sales
- Increased efficiency levels – reduced head count from c.2,400 to c.950
- Divested non-core
 businesses
- Gained GMP manufacturing status




Sales Evolution⁽¹⁾







uropean retail spending per capita year 2004







onsumption of DOT per capita (example:hypertension)









ZENTI

Source: IMS, CEGEDIM

elected dg comparison (32% of CZ retail market in value)

disease treatment group)	CZ	RO	ratio RO/CZ	% mod CZ	% mod RO	diff	ref DOT \$ price CZ	ref DOT \$ price RO	ratio RO/CZ		cost mn\$ for eq RO price	co mr fo er Ci pri
pertension (RAS) pertension (CCB)	119 077	18 662	<mark>16%</mark>	17% 41%	1% 9%	16% 32%		· · · · · · · · · · · · · · · · · · ·		losartan amlodipin	1 502	39
stro reflux	8 870	4 284	48%	54%	36%	18%				omeprazol	26	
pression	7 210	829	11%	72%	41%	31%	0,64	1,49	233%	mirtazapin	209	
ostatic benign	2 426	406	<mark>17%</mark>	100%	100%	0%	0,57	1,16	204%	finasteride	52	
lin	25 669	16 266	<mark>63%</mark>	9%	2%	7%	0,22	0,46	209%	nimesulide	95	
hizophraenia	2 038	449	<mark>22%</mark>	50%	48%	2%	1,72	3,60	209%	risperidone	126	
perlipidaemia	20 950	2 140	10%	63%	55%	8%	0,33	0,43	130%	simvastatin	178	1
OTAL	67 163	24 374	<mark>36%</mark>	406%	292%	<mark>114%</mark>	4,11	8,53	<mark>208%</mark>		2 188	7

1/3

1/2

2

Conclusion CZ/RO:

- Treatment of the population:
- **Penetration of modern molecules:**
- DOT price of modern molecules:

Price to get at CZ treatment leve

- 2,2 bn\$ at RO price
- 0,8 bn\$ at CZ price



- The provider of healthcare sets reimbursement at desired level defined on treatment/diagnosis/ATC3 (e.g. hypertension, depression), usually prioritizing the more effective/less side effect modern treatment
- The competition between the producers creates enormous pressure on price/co-payment to go down without any need of further interception



Example of the "generic" mechanism

Outcome of generics coming into CZ market	sales 1997 (mio CZK)	sales MAT/8/2005 (mio CZK)	DOT 1997 (mio)	DOT MAT/8/2005 (mio)	ratio sales	ratio DOTs	price of DOT 1997 (CZK)	price of DOT MAT/8/2 05 (CZK
gastro reflux disease	208	531	35	98	255%	278%		
modern (PPI)	97	419	3	59	<mark>433%</mark>	<mark>2253%</mark>	37	7
other	112	112	33	39	101%	120%	3	3
depression	223	860	19	82	385%	437%		
modern (3+4 generation)	142	738	6	68	521%	1067%	22	11
other	81	122	12	14	149%	112%	7	9

•	Modern drugs (including originals)	<u>Gastro</u>	<u>Depression</u>
	average DOT price lower	5x	2x
•	DOT consumption increased	3x	4x
•	Ratio of modern/old shifted from	7%	34%
	to	60%	84%
•	Costs increased by	2,5x	4x
IMS,	CEGEDIM		ZONTIV

Sets the quality standard



Guarantees availability for the healthcare

Sets the prices on a affordable level

<u>value for</u> <u>money</u>

availability



- Zentiva is a leading company in the CE Europe
- Romania becomes its key market after partnering Sicomed
- Primary care is the key factor to make modern treatment available on majority of patients on a cost-efficient basis
- A reimbursement system should allow inventions to be developed and at the same time drive modern treatment to majority of patients at an affordable cost (class effect, cathegorization committee)
- Romania has a strong reliable partner in Zentiva for building its modern and affordable healthcare system

